Home
News
Create
Screeners
Insights
Jeevan Scientific Technology
70.
05
+1.05
(+1.52%)
Market Cap
₹110.96 Cr
PE Ratio
-52.67
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+1.52%
1M
+4.55%
6M
+65.56%
1Y
+59.24%
5Y
-0.28%
View Company Insights
Latest news about Jeevan Scientific Technology
Jeevan Scientific Technology Receives US FDA Remote Regulatory Assessment Report
Jan 22, 2026
Jeevan Scientific Technology Limited announced the successful closure of US FDA Remote Regulatory Assessment and issuance of assessment report for its Hyderabad clinical pharmacology facility. The FDA review covered the period from October 17 to November 6, 2025, following the company's earlier disclosure in November 2025. This regulatory milestone demonstrates the company's commitment to international compliance standards in pharmaceutical operations.
Jeevan Scientific Promoters Acquire 30L Warrants in Preferential Allotment
Jan 06, 2026
Jeevan Scientific Acquires 60% Stake in Naya Pharma for ₹10 Cr
Dec 18, 2025
Jeevan Scientific Technology Limited Shareholders Approve Key Resolutions in EGM
Nov 12, 2025
Jeevan Scientific Technology Reports Net Loss in Q2 Amid Revenue Decline
Nov 12, 2025
More news about Jeevan Scientific Technology
08
Nov 25
Jeevan Scientific Technology Completes US FDA Remote Evaluation Successfully
Jeevan Scientific Technology Limited successfully completed a Remote Interactive Evaluation (RIE) by the US FDA for its Clinical Pharmacology facility. The evaluation, conducted from October 17 to November 6, 2025, covered BA/BE studies, operations, systems, and procedures, concluding with no critical observations. This outcome demonstrates the company's adherence to regulatory standards and may enhance its credibility in the pharmaceutical research sector.
18
Oct 25
Padmaja Private Trust Acquires 7.53% Stake in Jeevan Scientific Technology
Padmaja Private Trust has acquired a substantial 7.53% stake in Jeevan Scientific Technology Limited through preferential allotment of 15 lakh equity shares worth Rs 6 crore. The acquisition, completed on January 2, 2026, triggered SEBI disclosure requirements under Regulation 29(1) as the trust crossed the substantial acquisition threshold. This forms part of the company's successful Rs 30.74 crore capital raising initiative, which will fund expansion plans including API/formulation unit acquisitions and working capital requirements.
15
Oct 25
Jeevan Scientific Technology Unveils Rs. 30.74 Crore Capital Raising Plan
Jeevan Scientific Technology Limited (JSTL) has approved a capital raising plan of Rs. 30.74 crore through convertible warrants and equity shares. The plan includes issuing 35,00,000 convertible warrants at Rs. 40 per warrant and 41,85,000 equity shares at Rs. 40 per share. The warrants will be allotted to both promoters and non-promoters, while the equity shares are exclusively for non-promoters. The company also plans to increase its authorized share capital from Rs. 21 crore to Rs. 25 crore. An Extraordinary General Meeting is scheduled for November 12, 2025, to seek shareholder approval. Post-allotment, promoters' holding is expected to be 38.37%, with public holding at 61.63%.
Jeevan Scientific Technology
70.
05
+
1.
05
(+
1.
52
%)
1 Year Returns:
+59.24%
Industry Peers
Syngene International
435.05
(+
0.
16
%)
Indegene
477.15
(+
0.
52
%)
Suven Life Sciences
148.93
(-
1.
71
%)
Vimta Labs
470.40
(+
0.
60
%)
Take Solutions
46.68
(-
4.
44
%)
Bilcare
65.03
(+
1.
10
%)
Jeevan Scientific Technology
70.05
(+
1.
52
%)
Adeshwar Meditex
21.00
(-
100.
00
%)
Vanta Bioscience
19.89
(-
100.
00
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation